Table 1.
Patient characteristics at study entry
| Characteristic | N = 76 |
|---|---|
| Age, months | 12 (6.0) |
| Male sex, no. | 50 (66%) |
| Hospitalized at study entry, no. | 62 (82%) |
| OCS treatment, no. | 21 (28%) |
| Atopic eczema, no. | 13 (17%) |
| B‐eos, ×109/L | 0.27 (0.16‐0.58) |
| B‐eos > 0.4 × 109/L, no. | 32/74 (43%) |
| Atopic sensitization, no. | 22/74 (30%) |
| Food sensitization, no. | 21/74 (28%) |
| Aeroallergen sensitization, no. | 11/74 (15%) |
| Seasonal sensitization, no. | 5/74 (7%) |
| Perennial sensitization, no. | 10/74 (14%) |
| Parental asthma, no. | 16 (21%) |
| Parental smoking, no. | 30 (40%) |
| Maternal smoking, no. | 15 (20%) |
| Virus positive, no. | 76 (100%) |
| Rhinovirus, no. | 57 (75%) |
| Rhinovirus repeated during the first‐year follow‐up, no. | 47/56 (83%) |
| Rhinovirus genome load, copies/mL | 4000 (49‐17 000) |
| Rhinovirus genome load >7000 copies/mL, no. | 20/50 (40%) |
| Rhinovirus genome load >9000 copies/mL, no. | 18/50 (36%) |
| RSV, no. | 20 (26%) |
| Other virus, no. | 30 (40%) |
| Co‐infection, no. | 26 (34%) |
| 25‐hydroxyvitamin D, nmol/L | 88 (20) |
| 25‐hydroxyvitamin D > 75 nmol/L, no. | 52/73 (71%) |
| Regular ICS medication at 4‐year follow‐up | 37 (75%) |
| ICS discontinued ≥4 weeks before testing | 25/37 (68%) |
Data are expressed as mean (SD) when normally distributed and median (interquartile range) when not normally distributed or number (%) unless otherwise noted. B‐eos, blood eosinophil count; OCS, oral corticosteroid; RSV, respiratory syncytial virus.